ARS Pharmaceuticals Q3 earnings call highlights. ARS Pharmaceuticals (NASDAQ:SPRY) reported $33.4 million in third-quarter U.S. net product revenue from its needle-free epinephrine treatment neffy and reaffirmed its goal of reaching cash flow breakeven by the end of 2027. President and CEO Donn Casale said neffy's share of the U.S. epinephrine market exceeded 5%, up from 4% a year earlier, as end-user demand rose 42%. The company is shifting its commercial strategy toward targeted provider engagement while reducing broad consumer advertising. Total revenue rose to $37.7 million from $32.5 million in the third quarter of 2025. In addition to neffy's U.S. sales, the latest quarter included $2.6 million in supply revenue outside the U.S. and $1.7 million in collaboration revenue. Targeted accounts drive market share gains. Casale said neffy's share in field-targeted accounts rose to 9% from 6% a year earlier, compared with 2% in non-targeted accounts. The targeted accounts represent about 44% of the overall market opportunity, he said. More than 19,000 unique providers prescribed neffy during the quarter, up 49% year over year, bringing the total since launch to nearly 45,000, according to Casale. Chief Commercial Officer Meg Smith said the company is moving to an account-based sales approach that engages not only prescribers but also nurses, office staff and others involved in prescriptions and insurance authorizations. A new marketing campaign is expected to launch in early 2027. Smith said prior authorization is the biggest source of lost conversions from prescriptions to filled orders. Most prior authorization requests submitted for neffy are approved, she said, and the company is working with offices to support those submissions. Asked about CVS formulary coverage, Smith declined to discuss specific plans or payers. She said more than 80% of commercial lives have coverage for neffy, although some require prior authorization, and that ARS is in discussions with remaining Medicaid states and commercial plans. Casale said the company expects to complete the operational rollout of its commercial reset over the next quarter, with financial benefits becoming increasingly visible through the first half of 2027. Spending cuts and cash outlook. Total operating expenses were $71.9 million in the quarter, including stock-based compensation. Selling, general and administrative expenses fell to $43.5 million, more than 40% below the quarterly average for the first half of 2026. CFO Kathy Scott attributed much of the reduction to the discontinuation of linear television advertising, less broad consumer advertising and more targeted commercial spending. ARS plans to sustain the lower SG&A run rate through 2027. Research and development expenses were $18.3 million, including a one-time $12.5 million upfront payment for exclusive worldwide rights to certain intellectual property. Scott said the agreement supports expansion of the company's needle-free delivery platform in and beyond anaphylaxis, but did not provide further specifics. ARS ended the quarter with $138.4 million in cash, equivalents and short-term investments. Scott said the company expects to provide its full-year 2027 financial outlook alongside fourth-quarter results. During the question-and-answer session, Scott said inventory fluctuations were the primary reason net revenue did not rise as quickly as end-user demand. She said the company's gross-to-net figure remained around 50%, consistent with its expectations. ARS-2 trial data expected in 2027. ARS also is developing ARS-2 as a potential on-demand treatment for breakthrough flares in chronic spontaneous urticaria, a condition characterized by episodes of severe itching and hives. Casale said there are currently no FDA-approved therapies indicated to stop a breakthrough flare in progress. In a completed phase II trial, ARS-2 improved itch and hive scores beginning as early as five minutes after dosing, he said. An exploratory phase IIb trial is evaluating 0.5-milligram and 1-milligram doses to identify the minimum effective dose. ARS expects interim data in the first quarter of 2027 and full data later that year; the findings will help guide plans for a phase III registration program, Casale said. About ARS Pharmaceuticals (NASDAQ:SPRY). ARS Pharmaceuticals, Inc (NASDAQ: SPRY) is a biopharmaceutical company focused on developing and commercializing treatments for severe allergic reactions. The company's lead product is neffy (epinephrine nasal spray), a needle-free alternative to injectable epinephrine designed for the emergency treatment of allergic reactions, including anaphylaxis. Neffy was approved by the U.S. Food and Drug Administration in 2024 for adults and pediatric patients who weigh at least 30 kilograms. The product is intended to provide rapid, convenient administration without requiring a syringe or injector, which may help address barriers associated with the use of traditional epinephrine auto-injectors.

ARS Pharma to report third quarter 2026 financial results. SAN DIEGO, Oct. 28, 2026 (GLOBE NEWSWIRE) - ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions, today announced the company will host a conference call and webcast on Thursday, November 5, 2026, at 1:30 p.m. PT / 4:30 p.m. ET to review its third quarter 2026 financial results. Dial-in information for conference participants may be obtained by registering for the event. To access the webcast and slides, please visit the Events & Presentations page in the Investors & Media section of the Company's website. A replay of the webcast will be available for 30 days following the event. About ARS Pharmaceuticals, Inc. ARS Pharma is a biopharmaceutical company developing and commercializing treatments that help at-risk patients and their caregivers treat and prevent severe allergic reactions. The company is commercializing neffy(R)(epinephrine nasal spray), the only needle-free epinephrine approved by the U.S. Food & Drug Administration and European Medicines Agency, for the emergency treatment of Type I allergic reactions, including anaphylaxis, in adults and children weighing 33 lbs. (15kg) or more. The product is marketed as EURneffy(R) in the European Union and as 优敏速(R) in China. Leveraging its intranasal technology, ARS Pharma is also developing ARS-2, currently in a Phase 2b clinical trial, as a potential first treatment for acute flares of chronic spontaneous urticaria (CSU). For more information, visit www.ars-pharma.com.

Robbins LLP reminds investors of the securities fraud class action lawsuit against ARS Pharmaceuticals Inc. following a more than 23% stock drop on June 25, 2026. GlobeNewswire | Robbins LLP Today at 3:17pm PDT SAN DIEGO, Sept. 11, 2026 (GLOBE NEWSWIRE) - Robbins LLP reminds shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired ARS Pharmaceuticals Inc. (NASDAQ: SPRY) securities between March 9, 2026 and June 24, 2026 (the "Class Period"). ARS is a clinical stage biopharmaceutical company focused on the development and commercialization of neffy for needle-free intranasal delivery of epinephrine for emergency treatment of Type 1 allergic reactions, including anaphylaxis. Investors who suffered losses during the Class Period may have legal rights. If you want to seek appointment as lead plaintiff, contact Robbins LLP prior to the October 5, 2026 lead plaintiff deadline. Why Was ARS Pharmaceuticals Sued? According to the complaint, defendants provided investors with material information concerning ARS's expected timeline for expanded insurance coverage for its epinephrine nasal spray, neffy, with CVS Caremark. Defendants' statements included, among other things, confidence that this coverage would begin on July 1, 2026, and be in place for the summer and back-to-school allergy seasons. Plaintiff contends that defendants provided these overwhelmingly positive statements to investors while, at the same time, failing to adequately disclose the risk that the expanded insurance coverage may not be available by the July 1 deadline, and thus, ARS would not have the expanded insurance coverage for neffy with CVS Caremark for the summer and back-to-school seasons. Why Did ARS Stock Collapse? Plaintiff alleges that the truth emerged on June 24, 2026, after the market closed, when ARS published a press release announcing that the Company did not receive expanded insurance coverage for neffy through CVS Caremark by the guided July 1, 2026 deadline, which meant that ARS did not have expanded insurance coverage for neffy for the summer or back-to-school allergy seasons. ARS stated that CVS Caremark reserved its decision on the expanded insurance coverage for neffy until January 2027. On this news, the price of ARS's common stock declined from a closing market price of $10.54 per share on June 24, 2026 to $8.02 per share on June 25, 2025, a decline of over 23.9% in the span of just a single day. Who May Be Eligible? The lawsuit seeks to represent investors who purchased or otherwise acquired ARS Pharmaceuticals Inc. securities during the applicable Class Period. If you purchased ARS Pharmaceuticals Inc. stock during this period and suffered investment losses, you may have rights under the federal securities laws. What Is a Lead Plaintiff? The lead plaintiff is the investor appointed by the court to represent the interests of the proposed class throughout the litigation. Investors do not have to serve as lead plaintiff to potentially share in any recovery if the lawsuit is successful. Shareholders who wish to serve as lead plaintiff must seek appointment by October 5, 2026. Does It Cost Anything to Participate? No. Robbins LLP represents investors on a contingency fee basis. Contact Robbins LLP Investors seeking additional information about the ARS Pharmaceuticals Inc. securities class action may submit an inquiry through Robbins LLP's website, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. About Robbins LLP A recognized leader in shareholder rights litigation, Robbins LLP has helped restore more than $1 billion in value to shareholders and secured some of the largest recoveries in shareholder derivative litigation history. "Behind everything we do is the belief that companies should be governed responsibly, fiduciaries should be held accountable, and shareholders deserve transparency and fairness," said Brian J. Robbins, Founding Partner of Robbins LLP. To be notified if a class action against ARS Pharmaceuticals Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. This is a paid placement. For further inquiries, please contact GlobeNewswire directly.